Sulpiride‐induced tardive dystonia
Identifieur interne : 003B72 ( Istex/Corpus ); précédent : 003B71; suivant : 003B73Sulpiride‐induced tardive dystonia
Auteurs : Lucinda G. Miller ; JankovicSource :
- Movement Disorders [ 0885-3185 ] ; 1990.
English descriptors
- KwdEn :
Abstract
Sulpiride is a selective D2‐receptor antagonist with antipsychotic and antidepressant properties. Although initially thought to be free of extrapyramidal side effects, sulpiride‐induced tardive dyskinesia and parkinsonism have been reported occasionally. We studied a 37‐year‐old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy. We could not find any previous reports of sulpiride‐induced tardive dystonia.
Url:
DOI: 10.1002/mds.870050119
Links to Exploration step
ISTEX:F419D35E0DD2E2934DEA8404678245319EF21ED2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sulpiride‐induced tardive dystonia</title><author><name sortKey="Miller, Lucinda G" sort="Miller, Lucinda G" uniqKey="Miller L" first="Lucinda G." last="Miller">Lucinda G. Miller</name><affiliation><mods:affiliation>Department of Family Medicine, Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Jankovic" sort="Jankovic" uniqKey="Jankovic" last="Jankovic">Jankovic</name><affiliation><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F419D35E0DD2E2934DEA8404678245319EF21ED2</idno><date when="1990" year="1990">1990</date><idno type="doi">10.1002/mds.870050119</idno><idno type="url">https://api.istex.fr/document/F419D35E0DD2E2934DEA8404678245319EF21ED2/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003B72</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Sulpiride‐induced tardive dystonia</title><author><name sortKey="Miller, Lucinda G" sort="Miller, Lucinda G" uniqKey="Miller L" first="Lucinda G." last="Miller">Lucinda G. Miller</name><affiliation><mods:affiliation>Department of Family Medicine, Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Jankovic" sort="Jankovic" uniqKey="Jankovic" last="Jankovic">Jankovic</name><affiliation><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1990">1990</date><biblScope unit="vol">5</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="83">83</biblScope><biblScope unit="page" to="84">84</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">F419D35E0DD2E2934DEA8404678245319EF21ED2</idno><idno type="DOI">10.1002/mds.870050119</idno><idno type="ArticleID">MDS870050119</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinsonism</term><term>Sulpiride</term><term>Tardive dystonia</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Sulpiride is a selective D2‐receptor antagonist with antipsychotic and antidepressant properties. Although initially thought to be free of extrapyramidal side effects, sulpiride‐induced tardive dyskinesia and parkinsonism have been reported occasionally. We studied a 37‐year‐old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy. We could not find any previous reports of sulpiride‐induced tardive dystonia.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Lucinda G. Miller</name><affiliations><json:string>Department of Family Medicine, Baylor College of Medicine, Houston, Texas, U.S.A.</json:string></affiliations></json:item><json:item><name>Dr. Jankovic</name><affiliations><json:string>Department of Neurology, Baylor College of Medicine, Houston, Texas, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Sulpiride</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Tardive dystonia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinsonism</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Sulpiride is a selective D2‐receptor antagonist with antipsychotic and antidepressant properties. Although initially thought to be free of extrapyramidal side effects, sulpiride‐induced tardive dyskinesia and parkinsonism have been reported occasionally. We studied a 37‐year‐old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy. We could not find any previous reports of sulpiride‐induced tardive dystonia.</abstract><qualityIndicators><score>2.001</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 828 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>455</abstractCharCount><pdfWordCount>1305</pdfWordCount><pdfCharCount>8660</pdfCharCount><pdfPageCount>2</pdfPageCount><abstractWordCount>58</abstractWordCount></qualityIndicators><title>Sulpiride‐induced tardive dystonia</title><genre><json:string>Serial article</json:string></genre><host><volume>5</volume><pages><total>2</total><last>84</last><first>83</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1990</publicationDate><copyrightDate>1990</copyrightDate><doi><json:string>10.1002/mds.870050119</json:string></doi><id>F419D35E0DD2E2934DEA8404678245319EF21ED2</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/F419D35E0DD2E2934DEA8404678245319EF21ED2/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/F419D35E0DD2E2934DEA8404678245319EF21ED2/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/F419D35E0DD2E2934DEA8404678245319EF21ED2/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Sulpiride‐induced tardive dystonia</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>1990</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Sulpiride‐induced tardive dystonia</title><author><persName><forename type="first">Lucinda G.</forename><surname>Miller</surname></persName><affiliation>Department of Family Medicine, Baylor College of Medicine, Houston, Texas, U.S.A.</affiliation></author><author><persName><surname>Jankovic</surname><roleName type="degree">Dr.</roleName></persName><note type="correspondence"><p>Correspondence: Department of Nuerology, Baylor College of Medicine, Smith Tower, Suite 1801, 6550 Fannin, Houstan, TX 77030, U.S.A.</p></note><affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, U.S.A.</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1990"></date><biblScope unit="vol">5</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="83">83</biblScope><biblScope unit="page" to="84">84</biblScope></imprint></monogr><idno type="istex">F419D35E0DD2E2934DEA8404678245319EF21ED2</idno><idno type="DOI">10.1002/mds.870050119</idno><idno type="ArticleID">MDS870050119</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1990</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Sulpiride is a selective D2‐receptor antagonist with antipsychotic and antidepressant properties. Although initially thought to be free of extrapyramidal side effects, sulpiride‐induced tardive dyskinesia and parkinsonism have been reported occasionally. We studied a 37‐year‐old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy. We could not find any previous reports of sulpiride‐induced tardive dystonia.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Sulpiride</term></item><item><term>Tardive dystonia</term></item><item><term>Parkinsonism</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1990">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/F419D35E0DD2E2934DEA8404678245319EF21ED2/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/mds.v5:1</doi><numberingGroup><numbering type="journalVolume" number="5">5</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="1990">1990</coverDate></publicationMeta><publicationMeta level="unit" type="shortCommunication" position="19" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870050119</doi><idGroup><id type="unit" value="MDS870050119"></id></idGroup><countGroup><count type="pageTotal" number="2"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 1990 Movement Disorder Society</copyright><eventGroup><event type="firstOnline" date="2004-10-12"></event><event type="publishedOnlineFinalForm" date="2004-10-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">83</numbering><numbering type="pageLast">84</numbering></numberingGroup><correspondenceTo>Department of Nuerology, Baylor College of Medicine, Smith Tower, Suite 1801, 6550 Fannin, Houstan, TX 77030, U.S.A.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870050119.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="19"></count></countGroup><titleGroup><title type="main" xml:lang="en">Sulpiride‐induced tardive dystonia</title><title type="short" xml:lang="en">SULPIRIDE‐INDUCED TARDIVE DYSTONIA0</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Lucinda G.</givenNames><familyName>Miller</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2" corresponding="yes"><personName><honorifics>Dr.</honorifics><givenNames>Joseph</givenNames><familyName>Jankovic</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Family Medicine, Baylor College of Medicine, Houston, Texas, U.S.A.</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Sulpiride</keyword><keyword xml:id="kwd2">Tardive dystonia</keyword><keyword xml:id="kwd3">Parkinsonism</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Sulpiride is a selective D2‐receptor antagonist with antipsychotic and antidepressant properties. Although initially thought to be free of extrapyramidal side effects, sulpiride‐induced tardive dyskinesia and parkinsonism have been reported occasionally. We studied a 37‐year‐old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy. We could not find any previous reports of sulpiride‐induced tardive dystonia.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Sulpiride‐induced tardive dystonia</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>SULPIRIDE‐INDUCED TARDIVE DYSTONIA0</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Sulpiride‐induced tardive dystonia</title></titleInfo><name type="personal"><namePart type="given">Lucinda G.</namePart><namePart type="family">Miller</namePart><affiliation>Department of Family Medicine, Baylor College of Medicine, Houston, Texas, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="family">Jankovic</namePart><affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, U.S.A.</affiliation><description>Correspondence: Department of Nuerology, Baylor College of Medicine, Smith Tower, Suite 1801, 6550 Fannin, Houstan, TX 77030, U.S.A.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">shortCommunication</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1990</dateIssued><copyrightDate encoding="w3cdtf">1990</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">19</extent></physicalDescription><abstract lang="en">Sulpiride is a selective D2‐receptor antagonist with antipsychotic and antidepressant properties. Although initially thought to be free of extrapyramidal side effects, sulpiride‐induced tardive dyskinesia and parkinsonism have been reported occasionally. We studied a 37‐year‐old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy. We could not find any previous reports of sulpiride‐induced tardive dystonia.</abstract><subject lang="en"><genre>Keywords</genre><topic>Sulpiride</topic><topic>Tardive dystonia</topic><topic>Parkinsonism</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>83</start><end>84</end><total>2</total></extent></part></relatedItem><identifier type="istex">F419D35E0DD2E2934DEA8404678245319EF21ED2</identifier><identifier type="DOI">10.1002/mds.870050119</identifier><identifier type="ArticleID">MDS870050119</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1990 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B72 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003B72 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:F419D35E0DD2E2934DEA8404678245319EF21ED2
|texte= Sulpiride‐induced tardive dystonia
}}
| This area was generated with Dilib version V0.6.23. |  |